Condition: Relapsed Large B-cell Lymphoma · Refractory Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma (DLBCL) · Sponsor: Curocell Inc.
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
This description comes directly from the study's public registry record.
Bom-I Kwon, BSc · +82428633698 · bikwon@curocellbtx.com
Gunsoo Kim, MSc · gskim@curocellbtx.com
Always discuss trial participation with your own doctor first.
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| The Catholic University of Korea Seoul St. Mary's Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04836507